4.35
Mannkind Corp (MNKD) 最新ニュース
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq
Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio
MannKind EVP David Thomson sells shares worth $150,597 By Investing.com - Investing.com India
MannKind corp director Steven Binder sells $375,875 in stock By Investing.com - Investing.com Nigeria
MannKind EVP David Thomson sells shares worth $150,597 - Investing.com
MannKind corp director Steven Binder sells $375,875 in stock - Investing.com
MannKind CMO steps down, transition plan set - Investing.com
MannKind to Present at Upcoming Investor Conferences - The Globe and Mail
MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Call Transcript - Insider Monkey
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
MannKind: Q1 Earnings Snapshot - MySA
Earnings call transcript: MannKind Q1 2025 revenue beats, stock dips - Investing.com
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Gr - GuruFocus
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Growth | MNKD Stock News - GuruFocus
MannKind Corp Q1 2025 Earnings: EPS Meets Estimates at $0.04, Revenue Surpasses Expectations at $78 Million - GuruFocus
MannKind Corporation Reports First Quarter 2025 Financial Results - TradingView
MANNKIND CORP SEC 10-Q Report - TradingView
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Ex - GuruFocus
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 - The Globe and Mail
The Potential Rise in the Price of Mannkind Corp (MNKD) following insiders activity - knoxdaily.com
Solidion Technology Inc’s latest rating changes from various analysts - knoxdaily.com
MNKD (Mannkind Corp) may reap gains as insiders became active recently - knoxdaily.com
Mannkind Corp (MNKD) is looking forward to a strong quarter - Sete News
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) - Insider Monkey
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MannKind (NASDAQ:MNKD) Upgraded at Mizuho - Defense World
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Mizuho sets MannKind stock Outperform with $12 target - Investing.com
Mizuho sets MannKind stock Outperform with $12 target By Investing.com - Investing.com India
Diabetes Meets Racing: MannKind's Game-Changing Partnership With Type 1 Diabetic IndyCar Star - Stock Titan
MannKind To Support Conor Daly - Speed Sport
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options - Yahoo Finance
FTNT Stock Sees Surge of Approximately 1.11% in Last Five Days - knoxdaily.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
大文字化:
|
ボリューム (24 時間):